The safety and feasibility of Movement On renal replacement therapy via Vascath Evaluation in ICU patients: a pilot study

Monash Medical Centre Physiotherapy Department0 个研究点目标入组 40 人开始时间: 2011年7月13日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients admitted to ICU at MMC or Dandenong and commenced on continuous veno-venous haemodiafiltration (CVVHDF) via femoral vascath

•All eligible patients will be considered eligible to participate in a hip movement session unless they have any of the following clinical signs:
•*Extreme agitation or confusion (Richmond Agitation Sedation Scale 3 or 4)
•*Heart rate > 160 < 40 bpm or new arrhythmia developed (e.g. new onset atrial fibrillation)
•*Limb movement restricted by reasons other than the presence of a vascath.
•Patients will not be considered eligible to participate in a mobilization session (which includes sitting up at a minimum) if at the time of the planned session they have any of the following clinical signs:
•*Extreme agitation or confusion (Richmond Sedation-Agitation Scale 3 or 4)
•*Heart rate > 160 < 40 bpm or new arrhythmia developed (e.g. new onset atrial fibrillation)
•*Mean arterial blood pressure (MABP) < 60 mm Hg > 120 mm Hg
•*Patient requiring > 10 mcg/min noradrenaline (or equivalent vasopressor/ionotrope)
•*FiO2 > 0.6, with PaO2 < 65 mm Hg
•*Patient suffers a drop in SpO2 greater than 10% from resting level or SpO2 < 85%
•*Patient respiratory rate > 35
•*Patient temperature > 38.5 degrees
•*A stand will not be attempted in patients who are drowsy or unable to follow commands
•*Patient suffers new onset chest pain with suspected cardiac cause
•Cessation criteria
•Any session that is being carried out will be ceased if during the session, the patient meets any of the exclusion criteria not responsive to 2 minutes rest.

发起方

Monash Medical Centre Physiotherapy Department